Cash-strapped biotechnology company Jasper Therapeutics has gained a financial lifeline through a merger with a privately held immune drug developer.
Jasper said Thursday it has completed an all-stock acquisition of Kira Pharmaceuticals and, alongside that deal, raised $132 million in a private stock offering. The new funding will enable Jasper, which had just $14 million in cash at the end of March, to operate through the second half of 2028. The combined company will retain the Jasper stock ticker, but have a bigger pipeline that now includes two immune disease drugs Kira has been developing.
For Jasper, the deal represents a new chance to rebound from earlier stumbles that wiped out most of its market value. The company has been focusing on developing an experimental drug, briquilimab, for a form of chronic hives known as urticarias. But a faulty batch of drug product muddied results from a key study. The setback led Jasper to lay off half of its workforce and halt other drug research to preserve cash. Its previous chief medical officer departed the company as part of the restructuring.
Last month, Jasper formally announced it would seek “strategic alternatives,” a process that often leads to a sale or merger. That search led it to Kira, a biotech startup launched in 2020 and backed by investors like Foresite Capital, RA Capital Management and Vivo Capital.
Kira has been working on drugs targeting the “complement” system, a part of the immune system that helps wipe out pathogens and dead cells but can cause certain inflammatory conditions when dysregulated. One, called KP-104, is being tested in the blood disease paroxysmal nocturnal hemoglobinuria as well as certain rare kidney conditions such as IgA nephropathy. A second, KP-701, is a bispecific drug designed to depress B cell function.
Jasper is carrying both prospects forward. It intends to discuss a potential Phase 3 study of KP-701 in PNH, and report Phase 2 data from tests in kidney conditions next year. KP-701 could produce early-stage data in 2027 as well.
Kira shared Phase 2 data for KP-104 in PNH at the recent American Society of Hematology meeting. Though the results were from a small trial, they suggested the drug might have “best-in-class potential,” possibly even “exceeding” the benchmarks set by Novartis’ Fabhalta, wrote William Blair analyst Matt Phipps. KP-104 has “additional potential” in other conditions, like IgAN and C3 glomerulopathy, he added.
The company is also testing briquilimab in a kind of rare and deadly immune disease known as SCID, for which development was previously deprioritized. A pre-approval submission meeting is planned with the Food and Drug Administration, Jasper said.
Alongside the merger, Kira licensed out two other pipeline programs to Mirador Therapeutics, an immune disease drug developer led by previous Prometheus Biosciences executives. That pact involved KP-301, a long-acting antibody aimed at the immune protein C5, as well as a small molecule that homes in on the same target. Kira received $12 million upfront and is eligible for additional, unspecified milestone payments.
Facts Only
* Jasper completed an all-stock acquisition of Kira Pharmaceuticals.
* $132 million was raised in a private stock offering for the deal.
* The combined company will retain the Jasper stock ticker.
* The funding enables operation through the second half of 2028.
* Jasper previously had $14 million in cash at the end of March.
* Jasper focused on developing briquilimab for urticarias.
* A faulty drug batch muddied results from a key study related to briquilimab.
* The setback led Jasper to lay off half its workforce and halt other drug research.
* Jasper sought "strategic alternatives" last month, leading to the search that resulted in the acquisition of Kira.
* Kira is developing KP-104 and KP-701 targeting the complement system.
* Kira shared Phase 2 data for KP-104 in PNH at the American Society of Hematology meeting.
* Jasper is testing briquilimab in SCID.
* Kira licensed KP-301 and a small molecule to Mirador Therapeutics.
Executive Summary
Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals and raised $132 million in a private stock offering to secure funding. This capital infusion allows the combined company to operate through the second half of 2028, building on existing cash reserves from March. The merged entity will retain the Jasper stock ticker and possess Kira’s pipeline, which includes two immune disease drugs. Jasper previously focused on developing briquilimab for urticarias but faced setbacks due to a faulty drug batch, leading to workforce reductions and halted research. The acquisition provided a chance for Jasper to rebound from prior market value losses.
Kira Pharmaceuticals is developing treatments targeting the complement system, with KP-104 being tested for paroxysmal nocturnal hemoglobinuria (PNH) and certain kidney conditions like IgA nephropathy, and KP-701 being a bispecific drug designed to depress B cell function. Kira has presented Phase 2 data for KP-104 in PNH, which suggested best-in-class potential in some areas. Furthermore, Jasper is testing briquilimab for SCID, and Kira licensed KP-301 and a small molecule targeting the complement system to Mirador Therapeutics.
Full Take
The narrative presents a classic transition from operational stagnation under duress to leveraged strategic repositioning, framed around high-risk, high-reward asset acquisition. The pattern involves taking a company in distress—one that experienced internal failures leading to layoffs and research halts—and using external capital to acquire an external pipeline. This suggests that the valuation of Jasper was implicitly low, making it susceptible to being acquired for its potential rather than its existing structure.
The underlying dynamic centers on the value inherent in immune-system targeting technologies. Kira's assets, particularly KP-104 showing "best-in-class potential" in PNH trials, establish a high intrinsic value that justifies the acquisition price and the subsequent fundraising. The mention of delayed research (SCID) suggests an internal conflict between immediate cash preservation and long-term scientific pursuits; external financing resolves this tension by prioritizing pipeline development over short-term operational constraints.
The interaction with Mirador Therapeutics demonstrates a secondary layering of asset management, where successful pipeline assets are leveraged for further deals, indicating that the value chain extends beyond the immediate acquisition to include licensing and strategic alignment across related therapeutic areas. The risk lies in whether the injection of new capital fully resolves the structural weaknesses exposed by the previous research failures or if it merely buys time to execute an already flawed strategy under a larger financial umbrella. What is the true measure of success for Jasper—the survival of the entity, or the successful advancement of the immune pipeline?
Sentinel — Human
The text reads like standard financial/biotech reporting, synthesizing details from company announcements and expert commentary about a merger and drug pipeline update.